Effects of glycation on meloxicam binding to human serum albumin

The current study reports a binding of meloxicam a pharmacologically important new generation, non-steroidal anti-inflammatory drug to glycated form of the human serum albumin (HSA). The interaction of the meloxicam with nonglycated and glycated albumin has been studied at pH 7.4 in 0.05 M sodium phosphate buffer with 0.1 M NaCl, using fluorescence quenching technique and circular dichroism spectroscopy.Results of the present study have shown that the meloxicam could bind both forms of albumin glycated and nonglycated at a site, which was close to the tryptophan residues. Similarly, how for native albumin glycated form has had one high affinity site for the drug with association constants of the order of 105 M−1. The glycation process of the HSA significantly has affected the impact of the meloxicam on the binding of other ligands such as warfarin and bilirubin. The affinity of the glycated albumin for bilirubin as for native albumin has been reduced by meloxicam but observed effect was weaker by half (about 20%) compared with nonglycated albumin. In contrast to the native albumin meloxicam binding to glycated form of the protein only slightly affected the binding of warfarin. It seemed possible that the effects on warfarin binding might be entirely attributable to the Lys 199 modification which was in site I.

► Meloxicam is a pharmacologically important new generation, non-steroidal anti-inflammatory drug.
► The interaction of meloxicam with nonglycated and glycated albumin has been studied using fluorescence quenching technique and circular dichroism spectroscopy.
► Meloxicam could bind to both forms of albumin glycated and nonglycated.
► Similarly how for native albumin glycated form has one high affinity site for the drug with association constants of the order of 105 M−1.
► Glycation process of HSA significantly affects the impact of meloxicam on the binding of other ligands such as warfarin and bilirubin.